Senseonics ups loan capacity to $140M, securing funds to support operations through 2028 and new product launches.

Senseonics Holdings has amended its loan agreement with Hercules Capital to increase borrowing capacity from $100 million to $140 million. This includes $20 million in near-term loan commitments and potential future tranches up to $85 million, subject to conditions. With $35 million already borrowed and additional equity funding, Senseonics expects to have enough cash to fund operations into 2028, supporting the launch of its Freedom product and continued commercialization of Eversense 365. The expanded financing strengthens Senseonics' ability to advance clinical trials and product development in diabetes monitoring technology.